25.09.2013 • Newsgas distributiongas pricesGazprom

Gazprom Plans LNG Import Terminal in Baltic Enclave

Russia's Gazprom is looking into building a liquefied natural gas (LNG) import terminal on the Baltic Sea to supply the country's Kaliningrad enclave, amid a spat with neighbouring Lithuania over gas prices and distribution.

Gazprom, the world's biggest gas producer, supplies around 2 billion cubic meters of gas per year to Kaliningrad via Lithuania, paying transit fees. However, Lithuania also buys its gas from Gazprom and, according to European Commission, pays more for the gas than any other EU state, leading to a dispute.

Gazprom said its Chief Executive Alexei Miller and Kaliningrad governor Nikolai Tsukanov had agreed to study the construction of an LNG import terminal, with an investment decision seen next year.

Gazprom had previously said in June it was looking into building an LNG plant in the Baltic Sea that would actually produce the gas, rather than just convert imported LNG.

Lithuania plans to start importing LNG itself in 2015 to reduce its dependence on Russian gas supplies, which totalled over 3 billion cubic metres in 2012 - small compared with Gazprom's total exports to Europe, but still a blow to the Russian company's revenues if that demand dried up.

Gazprom, which supplies a quarter of Europe's gas needs, is facing growing pressure from cash-strapped Western clients seeking to cut bills and to revise long-term oil-linked contracts.

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.